

**CANCER REPORTING IN CALIFORNIA:**  
**ABSTRACTING AND CODING PROCEDURES**  
**FOR HOSPITALS**  
**California Cancer Reporting System Standards, Volume I**

*Changes and Clarifications –14<sup>th</sup> Edition*  
*February 21, 2014*

**New Grade Sections for Cases Diagnosed 01/01/2014 forward**  
**(Old Grade Sections becoming historical for cases diagnosed on or before 12/31/13)**

<b><u>New Volume I</u></b> <b><u>Section #</u></b>	<b><u>Data Item</u></b>	<b><u>Replacement to</u></b> <b><u>Volume I Section #</u></b>
V.3.7	Grade and Differentiation	V.3.5
V.3.7.1	Solid Tumors	V.3.5
V.3.7.2	Coding for Solid Tumors	V.3.5
V.3.7.3	Hematopoietic and Lymphoid Neoplasms	V.3.5.7
V.3.7.4	Breast – Nottingham or Bloom-Richardson (BR)Score Grade	V.3.5.8
V.3.7.5	Kidney Parenchyma – Fuhrman	V.3.5.10
V.3.7.6	Soft Tissue – Grade for Sarcomas	V.3.5
V.3.7.7	Prostate – Gleason Score	V.3.5.6

## **SECTION CHANGES**

### **I.1.6.6 Coding Resources**

- ✓ Added SEER Coding and Staging Manual 2014 and release date.
- ✓ Updated Hematopoietic Database version number and release date.
- ✓ Updated Hematopoietic Coding Manual release date.
- ✓ Updated SEER\*Rx Version number and release date.

### **I.1.6.7 CCR Reportability Guide**

- ✓ Added clarification to SKIN Section:
  - Non-Reportable section now includes: Early Melanoma and Evolving Melanoma.
  - EXCEPTIONS: Reportable skin cancer includes: Bullet #3 added to include “Early melanoma insitu” and “Evolving melanoma insitu.”
- ✓ Correction in Benign Schwannoma section, corrected to the SEER SINC #20130023 for C72.0.
- ✓ Added missing III classification to LIN as well as appropriate site codes for case reportability.
- ✓ Added Urine Cytology – Positive for malignancy to the Clarifications on Reportability section.
- ✓ Added Lymphoma In situ to Clarification on Reportability section.
- ✓ Formatting Changes

### **II.1.6.1 Reportable Terms**

- ✓ Added note regarding the reportability of **positive** urine cytology.

### **II.1.9.1 Reportability-Benign/Borderline Brain and CNS Tumors**

- ✓ Revised the introduction to the section to clarify that the CCR started collecting specific Benign/Borderline Brain and CNS tumors (listed in section) with a behavior code of 0 or 1, diagnosed 1/1/2001 forward while the National Standard Setters began with cases diagnosed 1/1/2004 forward.

### **II.2.4.1 Simultaneous Diagnosis**

- ✓ Updated link to Section V.3.7 Grade and Differentiation.

### **III.2.5.8 Country at DX**

- ✓ Updated formatting
- ✓ Added note stating: “Blanks are not allowed for this field.”

### **IV.1.7 Pathology**

- ✓ Updated link to Section V.3.7 Grade and Differentiation.

### **V.3.4.2 In-Situ Coding**

- ✓ Updated list to clarify LIN *III*.
- ✓ Updated list to include synonyms listed in the SEER Program Coding and Staging Manual 2014.

### **V.3.5 Grade and Differentiation**

- ✓ Added note to direct registrars to the new Grade section V.3.7, for cases diagnosed 01/01/2014 and forward.

#### **V.3.5.1 Mixed Differentiation**

- ✓ Added note to direct registrars to the new Grade section V.3.7.2, for cases diagnosed 01/01/2014 and forward.

#### **V.3.5.2 Microscopic Description**

- ✓ Added note to direct registrars to the new Grade section V.3.7.2, for cases diagnosed 01/01/2014 and forward.

#### **V.3.5.3 Variation in Terms for Degree of Differentiation**

- ✓ Added note to direct registrars to the new Grade section V.3.7.2, for cases diagnosed 01/01/2014 and forward.

#### **V.3.5.4 In Situ**

- ✓ Added note to direct registrars to the new Grade section V.3.7.2, for cases diagnosed 01/01/2014 and forward.

#### **V.3.5.5 Brain Tumors**

- ✓ Added notes for registrars to NOT use these rules for cases diagnosed 01/01/2014 and forward. Created link to the new Grade section V.3.7.2.

#### **V.3.5.6 Gleason’s Score**

- ✓ Added note to direct registrars to the new Grade section V.3.7.7, for cases diagnosed 01/01/2014 forward.

#### **V.3.5.7 Lymphomas and Leukemia’s**

- ✓ Added note to direct registrars to the new Grade section V.3.7.3, for cases diagnosed 01/01/2014 and forward.

### **V.3.5.8 Bloom Richardson Grade for Breast Cancer**

- ✓ Added note to direct registrars to the new Grade section V.3.7.4, for cases diagnosed 01/01/2014 and forward.

### **V.3.5.9 Grading Astrocytomas**

- ✓ Added note to direct registrars to the new Grade section V.3.7.2, for cases diagnosed 01/01/2014 and forward.

### **V.3.5.10 Fuhrman's Grade for Renal Cell Carcinoma**

- ✓ Added note to direct registrars to the new Grade section V.3.7.5, for cases diagnosed 01/01/2014 and forward.

## **V.3.7 Grade and Differentiation**

- ✓ New Volume I Section added for revised 2014 Grade Rules.
- ✓ Note and link added for cases diagnosed prior to or on 12/31/2013, section V.3.5.

### **V.3.7.1 Solid Tumors**

- ✓ New Volume I Section added for revised 2014 Grade Rules.
- ✓ Note and link added for cases diagnosed prior to or on 12/31/2013, section V.3.5.

### **V.3.7.2 Coding for Solid Tumors**

- ✓ New Volume I Section added for revised 2014 Grade Rules.
- ✓ Note and link added for cases diagnosed prior to or on 12/31/2013, section V.3.5.

### **V.3.7.3 Coding Grade for Hematopoietic and Lymphoid Neoplasms**

- ✓ New Volume I Section added for revised 2014 Grade Rules.
- ✓ Note and link added for cases diagnosed prior to or on 12/31/2013, section V.3.5.7.

### **V.3.7.4 Breast – Nottingham or Bloom-Richardson (BR) Score/Grade**

- ✓ New Volume I Section added for revised 2014 Grade Rules.
- ✓ Note and link added for cases diagnosed prior to or on 12/31/2013, section V.3.5.8.

### **V.3.7.5 Kidney Parenchyma – Fuhrman Nuclear Grade**

- ✓ New Volume I Section added for revised 2014 Grade Rules.
- ✓ Note and link added for cases diagnosed prior to or on 12/31/2013, section V.3.5.10.

### **V.3.7.3 Soft Tissue – Grade for Sarcomas**

- ✓ New Volume I Section added for revised 2014 Grade Rules.
- ✓ Note and link added for cases diagnosed prior to or on 12/31/2013, section V.3.5

### **V.3.7.7 Prostate – Gleason Score**

- ✓ New Volume I Section added for revised 2014 Grade Rules.
- ✓ Note and link added for cases diagnosed prior to or on 12/31/2013, section V.3.5.6.

### **V.5.8.1 Terms indicating In Situ**

- ✓ Updated list to clarify LIN *III*.
- ✓ Updated list to include synonyms listed in SEER Manual.

## **VI.3.2 Radiation Therapy Summary Codes**

- ✓ Made correction to the inversed descriptions for codes 2 and 3.

### VII.3.2 Place of Death - State

- ✓ Updated formatting
- ✓ Replaced word “Code” with “abbreviation” to signify that State is collected as an abbreviation, not a numeric code.

## **CHANGES to APPENDICES**

### **Appendix F**

- ✓ Updated with current link to California Reporting Facility Code Numbers.

### **Appendix K**

- ✓ Added the new 2014 Casefinding list.
- ✓ Made the old list a historical link.

### **Appendix S**

- ✓ Updated page to define Data Alerts and Data Memos.
- ✓ Created links to the pages on the California Cancer Registry website where the Data Alerts and Data Memos can be found.

### **Appendix U**

- ✓ Updated Histology Grade/Differentiation (pre 2014) with a link to old grade sections, V.3.5
- ✓ Added section for Histology Grade/Differentiation (post 2014) with a link to new grade sections, V.3.7.
- ✓ Corrected formatting and spelling errors.

### **Appendix Y Index to CS Site Specific Factors: (CSV02.05)**

- ✓ Updated the following Site Specific Sections for Fields that are NOT required with CSV02.05 and forward:

<b>Schema Name</b>	<b>SSF Fields NOT Required with CSV02.05</b>
Appendix	SSF 3: Carcinoembryonic Antigen (CEA) Lab Value
Bile Ducts Intra Hepatic	SSF 2: Fibrosis Score
	SSF 11: Primary Sclerosing Cholangitis (PSC)
Bile Ducts Perihilar	SSF 11: Primary Sclerosing Cholangitis (PSC)
Bone	SSF 3: Percent necrosis post neoadjuvant chemotherapy
Brain	SSF 4: Methylation of O6-Methylguanine-Methyltransferase (MGMT)
	SSF 5: Chromosome 1p: Loss of Heterozygosity (LOH)
	SSF 6: Chromosome 19q: Loss of Heterozygosity (LOH)
Breast	SSF 10: HER2: Fluorescence In-Situ Hybridization (FISH) Lab Value
	SSF 12: HER2: Chromogenic In Situ Hybridization (CISH) Lab Value
	SSF 21: Response to Neoadjuvant Therapy
Buccal Mucosa	SSF 11: Measured Thickness (Depth)
Cervix	SSF 1: FIGO Stage
CNS Other	SSF 4: Methylation of O6-Methylguanine-Methyltransferase (MGMT)
	SSF 5: Chromosome 1p: Loss of Heterozygosity (LOH)
	SSF 6: Chromosome 19q: Loss of Heterozygosity (LOH)
Colon	SSF 3: Carcinoembryonic Antigen (CEA) Lab Value
Corpus Adenosarcoma	SSF 1: FIGO Stage
Corpus Carcinoma	SSF 1: FIGO Stage
Fallopian Tube	SSF 1: FIGO Stage
Floor Mouth	SSF 11: Measured Thickness (Depth)
GIST Appendix	SSF 12: KIT Gene Immunohistochemistry (IHC)
GIST Colon	SSF 12: KIT Gene Immunohistochemistry (IHC)
GIST Esophagus	SSF 7: KIT Gene Immunohistochemistry (IHC)

GIST Peritoneum	SSF 6: KIT Gene Immunohistochemistry (IHC)
GIST Rectum	SSF 12: KIT Gene Immunohistochemistry (IHC)
GIST Small Intestine	SSF 7: KIT Gene Immunohistochemistry (IHC)
GIST Stomach	SSF 7: KIT Gene Immunohistochemistry (IHC)
Gum Lower	SSF 11: Measured Thickness (Depth)
Gum Other	SSF 11: Measured Thickness (Depth)
Gum Upper	SSF 11: Measured Thickness (Depth)
Kidney Renal Pelvis	SSF 2: Depth of Renal Parenchymal Invasion
Lip Lower	SSF 11: Measured Thickness (Depth)
Lip Other	SSF 11: Measured Thickness (Depth)
Lip Upper	SSF 11: Measured Thickness (Depth)
Liver	SSF 2: Fibrosis Score
	SSF 3: Alpha Fetoprotein (AFP) Lab Value
	SSF 4: Creatinine Value
	SSF 5: Creatinine Unit of Measure
	SSF 6: Total Bilirubin Value
	SSF 7: Total Bilirubin Unit of Measure
	SSF 8: International Normalized Ratio for Prothrombin Time (INR)
Lymphoma Ocular Adnexa	SSF 3: International Prognostic Index (IPI)
	SSF 6: Lactate Dehydrogenase (LDH)
Lymphoma	SSF 3: International Prognostic Index (IPI)
Melanoma Choroid	SSF 5: Chromosome 3 Status
	SSF 6: Chromosome 6p Status
	SSF 7: Chromosome 8q Status
	SSF 9: Mitotic Count
	SSF 10: Mean Diameter Nucleoli (MLN)
	SSF 11: Extravascular Matrix Patterns, Loops
	SSF 12: Extravascular Matrix Patterns, Networks
	SSF 13: Microvascular density (MVD)
Melanoma Ciliary Body	SSF 5: Chromosome 3 Status
	SSF 6: Chromosome 6p Status
	SSF 7: Chromosome 8q Status
	SSF 9: Mitotic Count
	SSF 10: Mean Diameter Nucleoli (MLN)
	SSF 11: Extravascular Matrix Patterns, Loops
	SSF 12: Extravascular Matrix Patterns, Networks
	SSF 13: Microvascular density (MVD)
Melanoma Iris	SSF 5: Chromosome 3 Status
	SSF 6: Chromosome 6p Status
	SSF 7: Chromosome 8q Status
	SSF 9: Mitotic Count
	SSF 10: Mean Diameter Nucleoli (MLN)
	SSF 11: Extravascular Matrix Patterns, Loops
	SSF 12: Extravascular Matrix Patterns, Networks
	SSF 13: Microvascular density (MVD)
Melanoma Skin	SSF 5: Serum Lactate Dehydrogenase (LDH) Lab Value
	SSF 6: LDH Upper Limits of Normal
Merkel Cell Penis	SSF 1: Measured Thickness (Depth)
Merkel Cell Scrotum	SSF 1: Measured Thickness (Depth)
Merkel Cell Skin	SSF 1: Measured Thickness (Depth)
Merkel Cell Vulva	SSF 1: Measured Thickness (Depth)
Mouth Other	SSF 11: Measured Thickness (Depth)
Nasal Cavity	SSF 11: Measured Thickness (Depth)
NET Ampulla	SSF 5: Serum Chromogranin A (CgA) Lab Value
	SSF 6: Urinary 5-HIAA Lab Value Level
NET Small Intestine	SSF 11: Serum Chromogranin A (CgA) Lab Value
	SSF 12: Urinary 5-HIAA Lab Value Level
NET Stomach	SSF 11: Serum Chromogranin A (CgA) Lab Value
	SSF 12: Urinary 5-HIAA Lab Value Level

Ovary	SSF 2: FIGO Stage
Palate Hard	SSF 11: Measured Thickness (Depth)
Peritoneum Female Gen	SSF 2: FIGO Stage
Placenta	SSF 2: FIGO Stage
Prostate	SSF 11: Gleason's Tertiary Pattern Value on Prostatectomy/Autopsy
Rectum	SSF 3: Carcinoembryonic Antigen (CEA) Lab Value
Scrotum	SSF 1: Measured Thickness (Depth)
Sinus Ethmoid	SSF 11: Measured Thickness (Depth)
Sinus Maxillary	SSF 11: Measured Thickness (Depth)
Sinus Other	SSF 11: Measured Thickness (Depth)
Skin Eyelid	SSF 8: Pagetoid Spread
	SSF 10: Prior Radiation
Skin	SSF 1: Measured Thickness (Depth)
	SSF 11: Perineural Invasion
Small Intestine	SSF 3: Carcinoembryonic Antigen (CEA) Lab Value
Testis	SSF 6: Pre-Orchiectomy Alpha Fetoprotein (AFP) Lab Value
	SSF 8: Pre-Orchiectomy Human Chorionic Gonadotropin (hCG) Lab Value
Tongue Anterior	SSF 11: Measured Thickness (Depth)
Vagina	SSF 1: FIGO Stage
	SSF 2: Pelvic Nodal Status
	SSF 3: Assessment Method of Pelvic Nodal Status
	SSF 4: Para-Aortic Nodal Status
	SSF 5: Assessment Method of Para-Aortic Nodal Status
	SSF 6: Distant (Mediastinal, Scalene) Node Status
	SSF 7: Assessment Method of Distant (Mediastinal, Scalene) Node Status
Vulva	SSF 10: FIGO Stage